DC-S239 is a selective histone methyltransferase SET7 inhibitor with an IC 50 value of 4.59 μM. DC-S239 also displays selectivity for DNMT1 , DOT1L , EZH2 , NSD1, SETD8 and G9a. DC-S239 has anticancer activity.
Storage Temp
Store at -80°C
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Product Description
DC-S239 is a selective histone methyltransferase SET7 inhibitor with an IC 50 value of 4.59 μM. DC-S239 also displays selectivity for DNMT1 , DOT1L , EZH2 , NSD1, SETD8 and G9a. DC-S239 has anticancer activity
In Vitro
DC-S239 inhibits DNMT1, DOT1L, EZH2, NSD1, SETD8 and G9a by less than 45%, while it inhibits SET7 by 90% at concentrations of 100 μM. DC-S239 (0-100 μM, 120 h) can inhibit the proliferation of MCF7, HL60 and MV4-11 cells in a dose-dependent manner but no significant effect on the activity of HCT116 and DHL4 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: MCF7, HL60, DHL4, MV4-11 and HCT116 cell lines Concentration: 0-100 μM Incubation Time: 120 h Result: Inhibited MCF7 and HL60 with the IC 50 values of 10.93 μM and 16.43 μM, respectively.
